155 related articles for article (PubMed ID: 33427877)
1. Stem cell origins of JMML.
Sundaravel S; Steidl U
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33427877
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.
Louka E; Povinelli B; Rodriguez-Meira A; Buck G; Wen WX; Wang G; Sousos N; Ashley N; Hamblin A; Booth CAG; Roy A; Elliott N; Iskander D; de la Fuente J; Fordham N; O'Byrne S; Inglott S; Norfo R; Salio M; Thongjuea S; Rao A; Roberts I; Mead AJ
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33416891
[TBL] [Abstract][Full Text] [Related]
3. Induced Pluripotent Stem Cells to Model Juvenile Myelomonocytic Leukemia: New Perspectives for Preclinical Research.
Wehbe Z; Ghanjati F; Flotho C
Cells; 2021 Sep; 10(9):. PubMed ID: 34571984
[TBL] [Abstract][Full Text] [Related]
4. Panobinostat inhibits the proliferation of CD34
Kurata T; Matsuda K; Hirabayashi K; Shigemura T; Sakashita K; Nakahata T; Koike K
Pediatr Blood Cancer; 2018 Nov; 65(11):e27261. PubMed ID: 30014555
[TBL] [Abstract][Full Text] [Related]
5. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828
[TBL] [Abstract][Full Text] [Related]
6. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.
Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K
J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639
[TBL] [Abstract][Full Text] [Related]
7. Juvenile myelomonocytic leukemia.
Satwani P; Kahn J; Dvorak CC
Pediatr Clin North Am; 2015 Feb; 62(1):95-106. PubMed ID: 25435114
[TBL] [Abstract][Full Text] [Related]
8. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
9. [Clinical Study on Treatment of Juvenile Myelomonocytic Leukemia with Haploidentical-Hematopoietic Stem Cell Transplantation].
Ding L; Zhu H; Han DM; Wang ZD; Zheng XL; Dong L; Yan HM; Liu J; Zhu L; Xue M; Guo ZK; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1524-1527. PubMed ID: 29070137
[TBL] [Abstract][Full Text] [Related]
10. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
Sakashita K; Kato I; Daifu T; Saida S; Hiramatsu H; Nishinaka Y; Ebihara Y; Ma F; Matsuda K; Saito S; Hirabayashi K; Kurata T; Uyen LT; Nakazawa Y; Tsuji K; Heike T; Nakahata T; Koike K
Leukemia; 2015 Mar; 29(3):606-14. PubMed ID: 25102944
[TBL] [Abstract][Full Text] [Related]
11. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
[TBL] [Abstract][Full Text] [Related]
12. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
McCullough KB; Kuhn AK; Patnaik MM
Curr Hematol Malig Rep; 2021 Jun; 16(3):256-266. PubMed ID: 33728588
[TBL] [Abstract][Full Text] [Related]
13. Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
Pearson S; Guo B; Pierce A; Azadbakht N; Brazzatti JA; Patassini S; Mulero-Navarro S; Meyer S; Flotho C; Gelb BD; Whetton AD
J Proteome Res; 2020 Jan; 19(1):194-203. PubMed ID: 31657576
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of juvenile myelomonocytic leukemia.
Sakashita K; Matsuda K; Koike K
Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases].
Yang WY; Liu LP; Liu F; Qi BQ; Chang LX; Zhang L; Chen XJ; Zou Y; Chen YM; Guo Y; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Mar; 25(3):265-271. PubMed ID: 36946161
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Neoplasms Presenting with Monocytosis.
Greenmyer JR; Kohorst M
Curr Hematol Malig Rep; 2021 Jun; 16(3):235-246. PubMed ID: 33630234
[TBL] [Abstract][Full Text] [Related]
20. [Advances in the treatment of juvenile myelomonocytic leukemia].
Cai YL; Zhang JL; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Nov; 20(11):958-963. PubMed ID: 30477631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
